当前位置: X-MOL 学术J. Am. Coll. Cardiol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The FINE ART of Interpreting Health Status Benefits in Clinical Trials
Journal of the American College of Cardiology ( IF 21.7 ) Pub Date : 2024-11-26 , DOI: 10.1016/j.jacc.2024.10.095
John A. Spertus, David J. Cohen, Suzanne V. Arnold

Section snippets

Funding Support and Author Disclosures

Dr Spertus has served as a consultant on patient-reported outcomes and evidence evaluation to Alnylam, AstraZeneca, Bayer, Janssen, Bristol Myers Squibb, Terumo, Cytokinetics, and Imbria; has received research grants from the National Institutes of Health, the Patient-Centered Outcomes Research Institute, the American College of Cardiology Foundation, BridgeBio, Bristol Myers Squibb, Cytokinetics, Imbria, and Janssen; owns the copyright to the Seattle Angina Questionnaire, Kansas City


中文翻译:


在临床试验中解释健康状况益处的 FINE ART


 部分片段


资金支持和作者披露


Spertus 博士曾担任 Alnylam、阿斯利康、拜耳、杨森、百时美施贵宝、Terumo、Cytokinetics 和 Imbria 的患者报告结果和证据评估顾问;已获得美国国立卫生研究院、以患者为中心的结果研究所、美国心脏病学会基金会、BridgeBio、百时美施贵宝、Cytokinetics、Imbria 和 Janssen 的研究资助;拥有堪萨斯城西雅图心绞痛调查问卷的版权
更新日期:2024-11-26
down
wechat
bug